Cardiovascular effects of frequent intensive hemodialysis

Seminars in Dialysis

Volumn 17, Issue 2, 2004, Pages 99-103

  Chan, Christopher T ^a,b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; PHOSPHATE; UREMIC TOXIN; VASOACTIVE AGENT;

BLOOD PRESSURE REGULATION; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; HEART VENTRICLE REMODELING; HEMODIALYSIS; HOME DIALYSIS; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY FAILURE; PATHOPHYSIOLOGY; REVIEW; SODIUM RETENTION; WATER RETENTION;

APPOINTMENTS AND SCHEDULES; CARDIOVASCULAR SYSTEM; HEMODIALYSIS, HOME; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS; RISK FACTORS;

EID: 2342426601     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0894-0959.2004.17204.x     Document Type: Review

References (51)

1. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119, 1998
2. Owen WF Jr, Chertow GM, Lazarus JM, Lowrie EG: Dose of hemodialysis and survival: differences by race and sex. JAMA 280:1764-1768, 1998
3. Zoccali C, Mallamaci F, Tripepi G: Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl 85:105-110, 2003
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5:2024-2031, 1995
5. Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE: Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 11:912-916, 2000
6. DePalma JR, Pecker EA, Gordon A, Maxwell MH: A new compact automatic home hemodialysis system. Trans Am Soc Artif Intern Organs 14:152-159, 1968
7. Uldall R, Ouwendyk M, Francoeur R, Wallace L, Sit W, Vas S, Pierratos A: Slow nocturnal home hemodialysis at the Wellesley Hospital. Adv Ren Replace Ther 3:133-136, 1996
8. Pierratos A: Daily hemodialysis: why the renewed interest? Am J Kidney Dis 32:S76-S82, 1998
9. Horl MP, Horl WH: Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 39:227-244, 2002
10. London GM: Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 16:85-94, 2003
11. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, Metivier F: Cardiac and arterial interactions in end-stage renal disease. Kidney Int 50:600-608, 1996
12. Lins RL, Elseviers M, Rogiers P, Van Hoeyweghen RJ, De Raedt H, Zachee P, Daelemans RA: Importance of volume factors in dialysis related hypertension. Clin Nephrol 48:29-33, 1997
13. Chaignon M, Chen WT, Tarazi RC, Bravo EL, Nakamoto S: Effect of hemodialysis on blood volume distribution and cardiac output. Hypertension 3:327-332, 1981
14. Zoccali C, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12:1508-1515, 2001
15. Atherton JJ, Moore TD, Lele SS, Thomson HL, Galbraith AJ, Belenkie I, Tyberg JV, Frenneaux MP: Diastolic ventricular interaction in chronic heart failure. Lancet 349:1720-1724, 1997
16. Onesti G, Kim KE, Greco JA, del Guercio ET, Fernandes M, Swartz C: Blood pressure regulation in end-stage renal disease and anephric man. Circ Res 36:145-152, 1975
17. London G, Guerin A, Pannier B, Marchais S, Benetos A, Safar M: Increased systolic pressure in chronic uremia. Role of arterial wave reflections. Hypertension 20:10-19, 1992
18. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF Jr: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287:1548-1555, 2002
19. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, Metivier F, Adda H, Safar ME: Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 12:2759-2767, 2001
20. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ, Safar ME: Arterial wave reflections and survival in end-stage renal failure. Hypertension 38:434-438, 2001
21. Morris ST, McMurray JJ, Spiers A, Jardine AG: Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int 60:1077-1082, 2001
22. Palmer RM, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526, 1987
23. Vallance P, Leone A, Calver A, Collier J, Moncada S: Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 20(suppl 12):S60-S62, 1992
24. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-575, 1992
25. Weisensee D, Low-Friedrich I, Riehle M, Bereiter-Hahn J, Schoeppe W: In vitro approach to "uremic cardiomyopathy." Nephron 65:392-400, 1993
26. Nixon JV, Mitchell JH, McPhaul JJ Jr, Henrich WL: Effect of hemodialysis on left ventricular function. Dissociation of changes in filling volume and in contractile state. J Clin Invest 71:377-384, 1983
27. Parfrey PS, Harnett JD, Foley RN, Kent GM, Murray DC, Barre PE, Guttmann RD: Impact of renal transplantation on uremic cardiomyopathy. Transplantation 60:908-914, 1995
28. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607-617, 1998
29. London GM: Vascular disease and atherosclerosis in uremia. Blood Purif 19:139-142, 2001
30. Indridason OS, Quarles LD: Hyperphosphatemia in end-stage renal disease. Adv Ren Replace Ther 9:184-192, 2002
31. Amann K, Ritz E, Wiest G, Klaus G, Mall G: A role of parathyroid hormone for the activation of cardiac fibroblasts in uremia. J Am Soc Nephrol 4:1814-1819, 1994
32. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912-1918, 1992
33. Floras JS: Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 22:72A-84A, 1993
34. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cateliotti A, Stancanelli B, Malatino LS: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354-1359, 2002
35. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Candela V, Labate C, Tassone F: Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. J Hypertens 19:287-293, 2001
36. Zoccali C, Mallamaci F, Tripepi G: Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis patients. J Am Soc Nephrol 13:729-733, 2002
37. Zoccali C, Mallamaci F, Tripepi G: Nocturnal hypoxemia: a neglected cardiovascular risk factor in end-stage renal disease? Blood Purif 20:120-123, 2002
38. Katz AM: Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med 322:100-110, 1990
39. Woods JD, Port FK, Orzol S, Buoncristiani U, Young E, Wolfe RA, Held PJ: Clinical and biochemical correlates of starting "daily" hemodialysis. Kidney Int 55:2467-2476, 1999
40. Pierratos A, Ouwendyk M, Francoeur R, Vas S, Raj DS, Ecclestone AM, Langos V, Uldall R: Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 9:859-868, 1998
41. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 61:2235-2239, 2002
42. Fagugli RM, Reboldi G, Quintaliani G, Pasini P, Ciao G, Cicconi B, Pasticci F, Kaufman JM, Buoncristiani U: Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 38:371-376, 2001
43. Pierratos A: Daily hemodialysis: an update. Curr Opin Nephrol Hypertens 11:165-171, 2002
44. Chan CT, Mardirossian S, Faratro R, Richardson RM: Improvement in lower-extremity peripheral arterial disease by nocturnal hemodialysis. Am J Kidney Dis 41:225-229, 2003
45. Nesrallah G, Suri R, Moist L, Kortas C, Lindsay RM: Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis 42:13-17, 2003
46. Chan C, Harvey PJ, Pierratos A, Miller JA, Floras JS: Nocturnal hemodialysis lowers blood pressure, norepinephrine and improves endothelially mediated dilation [abstract]. Circulation 106:11-486, 2002
47. Hanly PJ, Pierratos A: Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 344:102-107, 2001
48. Chan C, Hanly P, Gabor J, Picton P, Pierratos A, Floras JS: Nocturnal hemodialysis lowers heart rate during sleep and normalizes its parasympathetic and sympathetic modulation [abstract]. Hemodial Int 7:89-90, 2003
49. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A: Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53:1399-1404, 1998
50. Kjellstrand CM, Evans RL, Petersen RJ, Shideman JR, von Hartitzsch B, Buselmeier TJ: The "unphysiology" of dialysis: a major cause of dialysis side effects? Kidney Int Suppl 2:30-34, 1975
51. Chan CT: Nocturnal hemodialysis: an attempt to correct the "unphysiology" of conventional intermittent renal replacement therapy. Clin Invest Med 25:233-235, 2002